Scholar Rock Holding (SRRK) Short term Debt (2017 - 2024)
Scholar Rock Holding (SRRK) posted quarterly Short term Debt of $1.6 million for Q2 2024, down 71.13% quarter-over-quarter from $5.5 million in Q1 2024.
Scholar Rock Holding (SRRK) Short term Debt (2017 - 2024) Analysis & Trends
Scholar Rock Holding's Short term Debt history runs 7 years deep, the most recent figure standing at $1.6 million for Q2 2024.
- In Q2 2024, Short term Debt changed N/A year-over-year to $1.6 million; the TTM figure through Jun 2024 stood at $1.6 million (changed N/A YoY), while the FY2023 annual figure was $1.3 million, changed N/A from the prior year.
- Short term Debt for Q2 2024 stood at $1.6 million, down from $5.5 million in the prior quarter.
- The five-year high for Short term Debt was $11.6 million in Q2 2022, with the low at $805000.0 in Q3 2022.
- The 4-year median for Short term Debt is $1.6 million (2024), against an average of $4.1 million.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | Scholar Rock Holding | 6.39 Bn | 6.39 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2024 | 1.59 Mn |
| Mar 31, 2024 | 5.50 Mn |
| Dec 31, 2023 | 1.33 Mn |
| Sep 30, 2022 | 805,000.00 |
| Jun 30, 2022 | 11.58 Mn |
| Mar 31, 2022 | 6.58 Mn |
| Dec 31, 2021 | 1.58 Mn |
| Mar 31, 2019 | 270,000.00 |
| Dec 31, 2018 | 424,000.00 |
| Sep 30, 2018 | 578,000.00 |
| Jun 30, 2018 | 731,000.00 |
| Dec 31, 2017 | 641,000.00 |